

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Currently Amended) A stable pharmaceutical composition ~~Stable pharmaceutical compositions~~ of 5,10-methylene-(6R)-, -(6S)-or -(6R,S)-tetrahydrofolate, comprising characterised in that the composition comprises 5,10-methylene-(6R)-, -(6S)-or -(6R,S)-tetrahydrofolic acid or a pharmaceutically acceptable salt of 5,10-methylene-(6R)-, -(6S)-or -(6R,S)-tetrahydrofolic acid and together with citrate, and has a pH of between 7.5 to and 10.5, ~~preferably between 8.5 and 9.5.~~

2. (Currently Amended) A stable pharmaceutical composition ~~Stable pharmaceutical compositions~~ according to claim 1, further comprising an additional together with further pharmaceutically acceptable active ingredient or an adjuvant ~~ingredients and adjuvants.~~

3. (Currently Amended) A pharmaceutical composition according to claim 2, wherein the characterised in that it comprises formaldehyde as an adjuvant is formaldehyde.

4. (Currently Amended) A pharmaceutical composition according to claim 2, wherein the additional characterised in that it comprises a further folate as a further active ingredient is folate.

5. (Currently Amended) A pharmaceutical composition according to claim 4, wherein the folate is characterised in that it comprises tetrahydrofolic acid or a salt and salts thereof as a further folate.

6. (Currently Amended) A pharmaceutical composition according to claim 1, wherein characterised in that the calcium salt or an acidic salt is used as the pharmaceutically acceptable salt of 5,10-methylene-(6R)-, -(6S)-or -(6R,S)-tetrahydrofolic acid is a calcium or an acidic salt thereof.

7. (Currently Amended) A pharmaceutical composition according to claim 2, wherein the additional characterised in that it comprises a cytostatic agent as a further active ingredient is a cytostatic agent.

8. (Currently Amended) A pharmaceutical composition according to claim 2, wherein the additional characterised in that it comprises a fluorinated pyrimidine derivative as a further active ingredient is a fluorinated pyrimidine compound.

9. (Currently Amended) A pharmaceutical composition according to claim 8, wherein the fluorinated pyrimidine compound is a characterised in that it comprises 5-fluoruracil or a 5-fluoruracil compound prodrug, particularly capecitabine (xeloda) as a fluorinated pyrimidine derivative.

10. (Previously Presented) A pharmaceutical composition according to claim 1, additionally comprising at least one antioxidant or a radical scavenger.

11. (Currently Amended) A pharmaceutical composition according to claim 10, wherein the antioxidant or radical scavenger is characterised in that it comprises vitamin C or reduced glutathione as an antioxidant or radical scavenger.

12. (Currently Amended) A pharmaceutical composition according to claim 1, which is in the form of characterised in that the composition exists as a lyophilisate, dry powder or dry mixture.

13. (Currently Amended) A pharmaceutical composition according to claim 1, which is in the form of characterised in that the composition exists as a lyophilisation solution.

14. (Currently Amended) A method of stabilizing a composition ~~compositions~~ comprising 5,10-methylene-(6R)-, -(6S)-or -(6R,S)-tetrahydrofolate according to claim 1, comprising treating characterised in that 5,10-methylene-(6R)-, -(6S)-or -(6R,S)-tetrahydrofolic acid is treated with citrate and bringing it is brought to a pH of between 7.5 and to 10.5, preferably between 8.5 and 9.5.

15. (Currently Amended) A method of preparing a composition according to claim 1, Use of compositions comprising bringing together a pharmaceutically acceptable salt of 5,10-methylene-(6R)-, -(6S)-or -(6R,S)-tetrahydrofolic acid and citrate at a pH of between 7.5 and to 10.5, preferably between 8.5 and 9.5, for producing a pharmaceutical preparation suitable for use for corresponding medical indications.

16. (New) A pharmaceutical composition according to claim 1, which has a pH of 8.5 to 9.5.

17. (New) A pharmaceutical composition according to claim 8, wherein the fluorinated pyrimidine compound is a capecitabine (xeloda).

18. (New) A method for treating a solid tumor, comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition according to claim 1.